Your browser doesn't support javascript.
loading
Susceptibility of low-density lipoprotein particles to aggregate depends on particle lipidome, is modifiable, and associates with future cardiovascular deaths.
Ruuth, Maija; Nguyen, Su Duy; Vihervaara, Terhi; Hilvo, Mika; Laajala, Teemu D; Kondadi, Pradeep Kumar; Gisterå, Anton; Lähteenmäki, Hanna; Kittilä, Tiia; Huusko, Jenni; Uusitupa, Matti; Schwab, Ursula; Savolainen, Markku J; Sinisalo, Juha; Lokki, Marja-Liisa; Nieminen, Markku S; Jula, Antti; Perola, Markus; Ylä-Herttula, Seppo; Rudel, Lawrence; Öörni, Anssi; Baumann, Marc; Baruch, Amos; Laaksonen, Reijo; Ketelhuth, Daniel F J; Aittokallio, Tero; Jauhiainen, Matti; Käkelä, Reijo; Borén, Jan; Williams, Kevin Jon; Kovanen, Petri T; Öörni, Katariina.
Afiliação
  • Ruuth M; Atherosclerosis Research Laboratory, Wihuri Research Institute, Haartmaninkatu 8, 00290 Helsinki, Finland.
  • Nguyen SD; Research Programs Unit, Faculty of Medicine, University of Helsinki, Haartmaninkatu 8, P.O. Box 63, 00014 University of Helsinki, Finland.
  • Vihervaara T; Atherosclerosis Research Laboratory, Wihuri Research Institute, Haartmaninkatu 8, 00290 Helsinki, Finland.
  • Hilvo M; Zora Biosciences, Biologinkuja 1, 02150 Espoo, Finland.
  • Laajala TD; Zora Biosciences, Biologinkuja 1, 02150 Espoo, Finland.
  • Kondadi PK; Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Tukholmankatu 8, P.O. Box 20, 00014 University of Helsinki, Finland.
  • Gisterå A; Department of Mathematics and Statistics, University of Turku, Vesilinnantie 5, 20014 University of Turku, Finland.
  • Lähteenmäki H; Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, SU Sahlgrenska, 41345 Gothenburg, Sweden.
  • Kittilä T; Department of Medicine, Karolinska University Hospital, Karolinska Institute, Solna 171 76 Stockholm, Sweden.
  • Huusko J; Atherosclerosis Research Laboratory, Wihuri Research Institute, Haartmaninkatu 8, 00290 Helsinki, Finland.
  • Uusitupa M; Atherosclerosis Research Laboratory, Wihuri Research Institute, Haartmaninkatu 8, 00290 Helsinki, Finland.
  • Schwab U; Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Yliopistonranta 1, P.O. Box 1627, 70211 Kuopio, Finland.
  • Savolainen MJ; Institute of Public Health and Clinical Nutrition, School of Medicine, University of Eastern Finland, Yliopistonranta 1, P.O. Box 1627, 70211 Kuopio, Finland.
  • Sinisalo J; Institute of Public Health and Clinical Nutrition, School of Medicine, University of Eastern Finland, Yliopistonranta 1, P.O. Box 1627, 70211 Kuopio, Finland.
  • Lokki ML; Institute of Clinical Medicine, Internal Medicine, Kuopio University Hospital, Puijonlaaksontie 2, P.O. Box 100, 70029 Kuopio, Finland.
  • Nieminen MS; Research Unit of Internal Medicine, University of Oulu, Pentti Kaiteran katu 1, P.O. Box 8000, 90014, Oulu, Finland.
  • Jula A; Medical Research Center, Oulu University Hospital, Pentti Kaiteran katu 1, P.O. Box 8000, 90014 Oulu, Finland.
  • Perola M; Heart and Lung Center, Helsinki University Hospital and University of Helsinki, Haartmaninkatu 4, P.O. Box 340, 00029 Helsinki, Finland.
  • Ylä-Herttula S; Transplantation Laboratory, Medicum, University of Helsinki, Haartmaninkatu 3, P.O. Box 21, 00014 Helsinki, Finland.
  • Rudel L; Heart and Lung Center, Helsinki University Hospital and University of Helsinki, Haartmaninkatu 4, P.O. Box 340, 00029 Helsinki, Finland.
  • Öörni A; Genomics and Biomarkers Unit, Department of Health, National Institute for Health and Welfare, Genomics and Biomarkers Unit, Mannerheimintie 166, P.O. Box 30, 00271 Helsinki, Finland.
  • Baumann M; Genomics and Biomarkers Unit, Department of Health, National Institute for Health and Welfare, Genomics and Biomarkers Unit, Mannerheimintie 166, P.O. Box 30, 00271 Helsinki, Finland.
  • Baruch A; Institute for Molecular Medicine Finland and Diabetes and Obesity Research Program, University of Helsinki, Haartmaninkatu 8, P.O. Box 63, 00014 University of Helsinki, Finland.
  • Laaksonen R; Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Yliopistonranta 1, P.O. Box 1627, 70211 Kuopio, Finland.
  • Ketelhuth DFJ; Heart Center and Gene Therapy Unit, Kuopio University Hospital, Puijonlaaksontie 2, P.O. Box 100, 70029 Kuopio, Finland.
  • Aittokallio T; Department of Biochemistry Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA.
  • Jauhiainen M; Information Systems, Åbo Akademi University, Fänriksgatan 3A, 20500 Turku, Finland.
  • Käkelä R; Meilahti Clinical Proteomics Core Facility, Faculty of Medicine, University of Helsinki, Haartmaninkatu 8, P.O. Box 63, 00014 University of Helsinki, Finland.
  • Borén J; Genentech Research and Early Development, 1 DNA Way Mailstop 258A, South San Francisco, CA 94080, USA.
  • Williams KJ; Zora Biosciences, Biologinkuja 1, 02150 Espoo, Finland.
  • Kovanen PT; Finnish Cardiovascular Research Center, University of Tampere, Kalevantie 4, 33100 Tampere, Finland.
  • Öörni K; Finnish Clinical Biobank Tampere, University Hospital of Tampere, Arvo Ylpön katu 6, 33520 Tampere, Finland.
Eur Heart J ; 39(27): 2562-2573, 2018 07 14.
Article em En | MEDLINE | ID: mdl-29982602
Aims: Low-density lipoprotein (LDL) particles cause atherosclerotic cardiovascular disease (ASCVD) through their retention, modification, and accumulation within the arterial intima. High plasma concentrations of LDL drive this disease, but LDL quality may also contribute. Here, we focused on the intrinsic propensity of LDL to aggregate upon modification. We examined whether inter-individual differences in this quality are linked with LDL lipid composition and coronary artery disease (CAD) death, and basic mechanisms for plaque growth and destabilization. Methods and results: We developed a novel, reproducible method to assess the susceptibility of LDL particles to aggregate during lipolysis induced ex vivo by human recombinant secretory sphingomyelinase. Among patients with an established CAD, we found that the presence of aggregation-prone LDL was predictive of future cardiovascular deaths, independently of conventional risk factors. Aggregation-prone LDL contained more sphingolipids and less phosphatidylcholines than did aggregation-resistant LDL. Three interventions in animal models to rationally alter LDL composition lowered its susceptibility to aggregate and slowed atherosclerosis. Similar compositional changes induced in humans by PCSK9 inhibition or healthy diet also lowered LDL aggregation susceptibility. Aggregated LDL in vitro activated macrophages and T cells, two key cell types involved in plaque progression and rupture. Conclusion: Our results identify the susceptibility of LDL to aggregate as a novel measurable and modifiable factor in the progression of human ASCVD.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença da Artéria Coronariana / Lipoproteínas LDL Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Animals / Female / Humans / Male / Middle aged Idioma: En Revista: Eur Heart J Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença da Artéria Coronariana / Lipoproteínas LDL Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Animals / Female / Humans / Male / Middle aged Idioma: En Revista: Eur Heart J Ano de publicação: 2018 Tipo de documento: Article